mja.com.au | The Medical Journal of Australia

Home | Issues | MJA shop | MJA Careers | Contact | Topics | Search | RSS  | Login | Buy full access

Letters

Unexpected benefits of bethanechol in adults with cerebral palsy

Warwick J Carter
MJA 2008; 189 (5): 293

To the Editor: Bethanechol is a parasympathomimetic agent similar to acetylcholine that is known to be a selective stimulant of smooth muscle in the gastrointestinal tract and urinary bladder. It is normally used to treat non-obstructive urinary retention and has not previously been known to have any effect on skeletal muscle.

Adults with cerebral palsy usually slowly deteriorate over the years, with gradually increasing muscle tone, worsening speech, mobility difficulties and a loss of independence. There has been no change in their management for decades.

While working in a residential facility for adults with cerebral palsy, we serendipitously found that bethanechol significantly reduced the muscle spasticity in a patient for whom it was initially used to treat micturition difficulty.

Seven other patients who were wheelchair-bound with cerebral palsy were then progressively given bethanechol in increasing doses. All patients and/or their carers were advised that the medication was being used experimentally, and all consented to participate in a clinical trial. The results are summarised in the Box.

In all patients, bethanechol treatment was ceased for a week once the clinical benefits had been established, and all deteriorated during that week.

None of the patients suffered any detectable side effects from the use of bethanechol, but many were already taking a proton-pump inhibitor that may have protected them from any gastrointestinal adverse effects.

A synergistic interaction between bethanechol and another medication (eg, diazepam) was excluded as an explanation for the results obtained, as no other medication was common to all patients.

Bethanechol’s effect seems to be long-lasting, as the first patient has now been using it for 6 months with no deterioration in his improved muscle tone.

A Medline search revealed no studies in which bethanechol had been used as a treatment for cerebral palsy. Although our sample was very small, the fact that every patient improved indicates that a larger trial of bethanechol for cerebral palsy is warranted.

Clinical outcomes for eight patients with cerebral palsy after treatment with bethanechol

Sex (age in years)

Diagnosis

Final daily dose of bethanechol*

Clinical effects


M (41)

Ataxic and spastic quadriplegia

60 mg

Reduced muscle spasm, improved joint movement and speech, improved sense of wellbeing

F (53)

Ataxic and spastic quadriplegia

60 mg

Improved arm movement and speech, looser muscle tone, more relaxed

F (47)

Spastic quadriplegia, kyphoscoliosis

60 mg

Able to abduct legs from previously clamped closed position, loss of leg spasm pain, improved speech, muscle spasm induced by touch eliminated

M (68)

Spastic quadriplegia, dysphagia

60 mg

Less stiffness, speech clearer, easier for carers to move, improved sense of wellbeing

M (58)

Rigid spastic quadriplegia

60 mg

Less limb muscle spasm, improved arm and trunk movement, markedly improved speech

F (44)

Spastic quadriplegia, epilepsy

60 mg

Improved arm and leg movement, easier to roll

M (49)

Spastic quadriplegia, athetosis

30 mg

Chronic spasmodic jerks ceased completely, speech better, able to play carpet bowls better, back extension improved

M (68)

Spastic quadriplegia, kyphoscoliosis

60 mg

Less muscle pain, less back spasm, easier for carers to lift, felt happier and more relaxed


* Given orally in three divided doses.

Acknowledgements: I would like to thank physiotherapist Diane Josephson and registered nurse Lynne Roche for their assistance with the study.

Warwick J Carter, General Practitioner

Brisbane, QLD.

wcarterATmedwords.com.au

(Received 11 Jun 2008, accepted 23 Jul 2008)


Home | Issues | MJA shop | Terms of use | MJA Careers | More... | Contact | Topics | Search | RSS 

mja.com.au | The Medical Journal of Australia  

©The Medical Journal of Australia 2008 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377